Key Drivers
- Low margins
- High leverage
- Positive annual FCF
AIAI Summary
ASTH's strategic pivot into AI-enabled Care Enablement and payer-risk contracts recasts it from a low-margin hospital operator into a growth story—provided management converts Prospect Health synergies (~$12–$15M), sustains quarterly FCF to drive de-leveraging from ~2.5x toward <2.0x, and executes payer transitions on schedule, because misses would quickly expose its high PE, cash-flow volatility, and large intangibles.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Low margins
- •High leverage
- •Positive annual FCF
ASTH generates solid revenue and annual free cash flow but delivers very low returns with high leverage, elevated valuation, large intangibles, and recent quarter cash volatility.
Price Behavior
Key Price Behavior Insights:
- •Short-term uptrend
- •Consolidation zone
- •Elevated volatility
Over the last month ASTH has moved up from about $19.86 to $24.23, consolidating near $24–$25.6 with resistance at $26.32 and support around $19.8–$20.3, so a break above $26.32 would signal resumed upside while a break below $24 then $20.3 would indicate a reversal amid elevated volatility.
Rapid jump into the $26s on 2026-03-02 followed by a pullback indicating event-driven volatility
Sentiment & News
Key News Insights:
- •Earnings beat
- •Investor outreach
- •Institutional sell-down
Astrana Health swung to a Q4 2025 adjusted EPS of $0.54 and beat revenue/earnings estimates, prompting a share gap-up and increased investor outreach and recognition, though offset by a notable institutional sell-down.
The earnings beat and quality recognition are near-term positive catalysts for the stock, but the крупная institutional stake reduction introduces ownership volatility to monitor
Similar Companies in Healthcare
Other companies in the same sector with AI ratings